TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8460064

Group type: EXPERIMENTAL
Intervention: End inspiratory occlusion times of 90 to 275 ms
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: End inspiratory occlusion times longer than 275 ms
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Occlusions between 300 and 450 ms
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Age range for applying this method
Number of subjects: 36
Study: 3535621

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (Rinexin) 50 mg twice daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 30218844

Group type: EXPERIMENTAL
Intervention: 3-month dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitor
Number of subjects: 2009
Study: 27018532

Group type: EXPERIMENTAL
Intervention: SBP + BAI
Number of subjects: 97

Group type: COMPARATOR
Intervention: SBP
Number of subjects: 97
Study: 25467378

Group type: EXPERIMENTAL
Intervention: Bilateral vapour ablation in addition to standard medical management
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard medical management alone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Adverse events monitoring
Number of subjects: 69
Study: 21842236

Group type: EXPERIMENTAL
Intervention: Free Hand technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Assisted Free Hand technique
Number of subjects: 20
Study: 20438514

Group type: COMPARATOR
Intervention: Conventional (potentially contaminated) dialysate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate
Number of subjects: 48
Study: 18640108

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg etomidate
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 2 mg/kg propofol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 5
Study: 17264833

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 12665540

Group type: EXPERIMENTAL
Intervention: 110% CP
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 90% CP
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 80% theta(L)
Number of subjects: 6
Study: 11013280

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m(2), 3-hour infusion) and cisplatin (80 mg/m(2)) every 21 days
Number of subjects: 414

Group type: COMPARATOR
Intervention: High-dose cisplatin (100 mg/m(2))
Number of subjects: 414
Study: 8780837

Group type: EXPERIMENTAL
Intervention: Naltrexone (1 mg/kg daily for 4 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1622413

Group type: EXPERIMENTAL
Intervention: Methotrexate sodium tablets (7.5 mg dose, three 2.5 mg tablets) administered after an overnight fast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Methotrexate sodium tablets (7.5 mg dose, three 2.5 mg tablets) administered within 10 minutes of consuming a high fat‐content breakfast
Number of subjects: 12
Study: 6421561

Group type: EXPERIMENTAL
Intervention: New glibenclamide preparation (Euglucon 5, HB 419)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional glibenclamide preparation (Euglucon N, HB 420)
Number of subjects: 12
Study: 31929499

Group type: EXPERIMENTAL
Intervention: Tunnel-like fistulectomy plus draining seton combined with incision of internal opening of anal fistula (TFSIA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cutting seton (Control)
Number of subjects: 80
Study: 29760159

Group type: EXPERIMENTAL
Intervention: MTX+ (methotrexate therapy with hydroxychloroquine added if no remission)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: MTX+
Number of subjects: 108

Group type: COMPARATOR
Intervention: Prediction model
Number of subjects: 108
Study: 27896461

Group type: EXPERIMENTAL
Intervention: TAP block using 20 mL of 0.375% ropivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo group using 20 mL of 0.9% normal saline infusion
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 64
Study: 24532502

Group type: EXPERIMENTAL
Intervention: Discontinuation of dual antiplatelet therapy (DAPT) due to unexpected requests for non-cardiac surgery or invasive procedures
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: Non-cardiac surgery or procedure performed after requests
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting stent implantation with 3-month DAPT
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: Timing of request for surgery or procedure
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: Overall outcomes related to DAPT discontinuation
Number of subjects: 2117
Study: 23731986

Group type: EXPERIMENTAL
Intervention: Irish set dancing classes once per week plus a weekly home program for 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard physiotherapy exercises
Number of subjects: 24
Study: 19895590

Group type: EXPERIMENTAL
Intervention: Intervention (MCID calculation for Mini Rhinoconjunctivitis Quality of Life Questionnaire)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Intervention (MCID calculation for peak nasal inspiratory flow)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Intervention (MCID calculation for total nasal symptoms score)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Intervention (Nasal NO measurement)
Number of subjects: 204
Study: 18801576

Group type: EXPERIMENTAL
Intervention: Phacoemulsification alone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Combined phacotrabeculectomy with adjunctive mitomycin C
Number of subjects: 72
Study: 15986752

Group type: EXPERIMENTAL
Intervention: Gluteal rotation flaps
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Gluteal V‐Y flaps
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Transposition flaps
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Surgical intervention with postoperative care
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Postoperative antibiotic therapy and late suture removal
Number of subjects: 74
Study: 12460865

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (three 5-minute cycles of ischemia of the contralateral limb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limb ischemia (20 minutes of upper limb ischemia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no remote preconditioning)
Number of subjects: 0
Study: 10874387

Group type: EXPERIMENTAL
Intervention: Fieller's confidence interval method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bootstrap confidence interval methods
Number of subjects: 0
Study: 7482373

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (implied control)
Number of subjects: 0
Study: 1753113

Group type: EXPERIMENTAL
Intervention: Staphylococcus saprophyticus infection
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Asymptomatic S. saprophyticus infection
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: S. saprophyticus as the cause of urinary tract infections
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Correlation with nephrolithiasis
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Catheter-induced infections
Number of subjects: 270
Study: 7125306

Group type: EXPERIMENTAL
Intervention: Fenoterol 2.5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fenoterol 5.0 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fenoterol 7.5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ephedrine 24 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31775696

Group type: EXPERIMENTAL
Intervention: GReat-Child Trial™ intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 29246256

Group type: EXPERIMENTAL
Intervention: Oral glycine (0.5 g/kg/day, dissolved in any liquid)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (glass sugar)
Number of subjects: 13
Study: 25648580

Group type: EXPERIMENTAL
Intervention: Tourniquet (T-group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No tourniquet (NT-group)
Number of subjects: 64
Study: 24825180

Group type: EXPERIMENTAL
Intervention: Long-term proton pump inhibitor therapy (>1 year)
Number of subjects: 0
Study: 22932247

Group type: EXPERIMENTAL
Intervention: Nasal septal cartilage combined with ePTFE (group A)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Autologous auricular cartilage grafts (group B)
Number of subjects: 118
Study: 19576351

Group type: EXPERIMENTAL
Intervention: CAPSID (Computerized Angioplasty Pressure Sensor and Inflator Device)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard manual percutaneous coronary intervention (Control)
Number of subjects: 310
Study: 17538639

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (TTG) 50 mg/day for 3 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel (TTG)
Number of subjects: 38
Study: 15779317

Group type: COMPARATOR
Intervention: Excite (EX, Ivoclar‐Vivadent) on enamel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Excite (EX, Ivoclar‐Vivadent) on dentin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AdheSE (AS, Ivoclar‐Vivadent) on dentin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Xeno CF II (X, Sanking Kogyo) on dentin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adper Prompt‐L‐Pop (AP, 3M ESPE) on dentin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AdheSE (AS, Ivoclar‐Vivadent) on enamel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Xeno CF II (X, Sanking Kogyo) on enamel
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adper Prompt‐L‐Pop (AP, 3M ESPE) on enamel
Number of subjects: 40
Study: 11782694

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Praxilene), 200 mg three times daily for 6 months
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 11195304

Group type: EXPERIMENTAL
Intervention: Attention shifting turned on
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention shifting turned off
Number of subjects: 0
Study: 9513821

Group type: EXPERIMENTAL
Intervention: Treatment for gastro-oesophageal reflux
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Treatment for non-ulcer dyspepsia with Helicobacter pylori eradication
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Treatment for duodenal ulceration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prokinetic agent for non-ulcer dyspepsia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 50
Study: 8443719

Group type: EXPERIMENTAL
Intervention: Cysteine (200 mg orally four times a day)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Methylmethionine sulfonium chloride (MMSC) (500 mg orally four times a day)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 172
Study: 3821139

Group type: EXPERIMENTAL
Intervention: Calea zacatechichi extracts (low doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calea zacatechichi extracts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 31355870

Group type: EXPERIMENTAL
Intervention: Acupuncture on the disease-affected meridian (DAM)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Acupuncture on the nonaffected meridian (NAM)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 404

Group type: COMPARATOR
Intervention: No acupuncture (wait list [WL] group)
Number of subjects: 404
Study: 30241722

Group type: EXPERIMENTAL
Intervention: Azithromycin (5 mg/kg per day for 21 days)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (22.5 mg/kg, twice daily for 21 days)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 236

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 236
Study: 27048694

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid 1g 10 min bolus followed by 1g 8h infusion
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 24754183

Group type: EXPERIMENTAL
Intervention: Reinforcing kidney, activating blood circulation and ovarian stimulation compound recipe (treatment group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clomiphene (control group)
Number of subjects: 60
Study: 22187510

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 17120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17120
Study: 20388052

Group type: EXPERIMENTAL
Intervention: IAsp CSII
Number of subjects: 61

Group type: COMPARATOR
Intervention: IAsp MDI
Number of subjects: 61

Group type: COMPARATOR
Intervention: HI MDI
Number of subjects: 61
Study: 18373490

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg once daily (q.d.)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily (b.i.d.)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg with a 200 mg redose (p.r.n.) on day 1
Number of subjects: 276
Study: 15836932

Group type: EXPERIMENTAL
Intervention: Non-invasive electrogoniometer measurements
Number of subjects: 9
Study: 12431168

Group type: EXPERIMENTAL
Intervention: Educational intervention (pamphlet with written information and illustrations)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (verbal checklist of risks only)
Number of subjects: 121
Study: 9886446

Group type: EXPERIMENTAL
Intervention: Intracranial pressure (ICP) monitoring
Number of subjects: 110

Group type: COMPARATOR
Intervention: Other secondary insults (not specified)
Number of subjects: 110
Study: 7792793

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (K‐Can) 50 mg/day for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Furosemide 25 mg for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 2 weeks before each treatment
Number of subjects: 50
Study: 1673723

Group type: EXPERIMENTAL
Intervention: Astemizole (H1 receptor blocker)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31086126

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus administered via nasogastric tube on Day 1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus administered via nasogastric tube on Day 3
Number of subjects: 10
Study: 27858183

Group type: EXPERIMENTAL
Intervention: THP (25 mg/m2 × 11)
Number of subjects: 276

Group type: COMPARATOR
Intervention: DNR (30 mg/m2 × 11)
Number of subjects: 276
Study: 26109819

Group type: EXPERIMENTAL
Intervention: Recombinant streptokinase (rSK) suppositories (200000 IU every 8 hours for the first 3 units, then every 12 hours until 8 administrations completed)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Hydrocortisone acetate suppositories (25 mg every 8 hours up to a maximum of 24 administrations)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Recombinant streptokinase (rSK) suppositories (both schedules)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Hydrocortisone acetate suppositories
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Recombinant streptokinase (rSK) suppositories
Number of subjects: 421
Study: 22987606

Group type: EXPERIMENTAL
Intervention: Individual Patient Data (IPD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aggregate Data (AD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of IPD and AD
Number of subjects: 0
Study: 21851342

Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion at 3 cm
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion at 5 cm
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Epidural catheter insertion at 7 cm
Number of subjects: 102
Study: 19463125

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17535995

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 0.33 mg/kg body weight per week for a mean of 6.7 years
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 31
Study: 15470332

Group type: EXPERIMENTAL
Intervention: SJW extract with high HYF content (900 mg/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: SJW extract with low HYF content (900 mg/d)
Number of subjects: 10
Study: 11468503

Group type: EXPERIMENTAL
Intervention: Healthwise Communities Project (free self-care resources)
Number of subjects: 1812
Study: 9503767

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral interventions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 7508396

Group type: EXPERIMENTAL
Intervention: 960 mg cotrimoxazole and 10 mg oxazepam (group B)
Number of subjects: 83

Group type: COMPARATOR
Intervention: 960 mg cotrimoxazole (group A)
Number of subjects: 83
Study: 2730051

Group type: EXPERIMENTAL
Intervention: Juzentaiho-to (JTT) combined with chemoendocrine therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Chemoendocrine therapy only
Number of subjects: 130
Study: 807995

Group type: EXPERIMENTAL
Intervention: Flexical diet (semi‐hydrolyzed diet: 10 g % casein hydrolsate; 14 g % triglycerides, 20% of which medium chain; 66% disaccharides)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal diet (control group)
Number of subjects: 18
Study: 31161580

Group type: EXPERIMENTAL
Intervention: +O-desmethyltramadol (200 mg extended-release tablets)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29250545

Group type: EXPERIMENTAL
Intervention: Simvastatin (preoperative and postoperative administration)
Number of subjects: 130
Study: 25450879

Group type: COMPARATOR
Intervention: Cisplatin 25 mg/m² and etoposide 100 mg/m² intravenously on days 1 to 3 (control arm)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Cisplatin 25 mg/m² and etoposide 100 mg/m² combined with bevacizumab 7.5 mg/kg intravenously on day 1 (experimental arm)
Number of subjects: 206
Study: 23539943

Group type: EXPERIMENTAL
Intervention: Health education program using the PRECEDE‐PROCEED Model
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Health education program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no health education program)
Number of subjects: 100
Study: 21735279

Group type: EXPERIMENTAL
Intervention: Vibrotactile neurofeedback training for 10 days based on sway analysis
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 36
Study: 19761721

Group type: EXPERIMENTAL
Intervention: Subcutaneous epoietin-beta (0.3 ml = 4000 IU)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Subcutaneous darbepoietin-alpha (0.5 ml = 20 microg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline placebo (0.3 ml)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline placebo (0.5 ml)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Subcutaneous epoietin-beta
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Subcutaneous darbepoietin-alpha
Number of subjects: 42
Study: 16766740

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia via endovascular approach
Number of subjects: 10
Study: 15293466

Group type: EXPERIMENTAL
Intervention: Combination of traditional Chinese medicine and western medicine with massage and functional exercise (trial group)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Traditional Chinese medicine and western medicine without massage and functional exercise (control group)
Number of subjects: 83
Study: 11062863

Group type: EXPERIMENTAL
Intervention: 10 mg of zolpidem (ZLP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7.5 mg of zopiclone (ZPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZLP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZPC
Number of subjects: 0
Study: 9323395

Group type: EXPERIMENTAL
Intervention: Educational interventions in 6 intervention subsites
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control subsites (5)
Number of subjects: 11
Study: 8405631

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol transdermally 0.05 mg/day on days 1‐24 and medroxyprogesterone acetate 10 mg/day orally on days 15‐24 (sequential schedule)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol transdermally 0.05 mg/day and medroxyprogesterone acetate 2.5 mg/day orally on days 1‐24 (continuous schedule)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol 0.05 mg/day continuously (in patients who had total abdominal hysterectomy+bilateral salphingooopherectomy)
Number of subjects: 60
Study: 2945332

Group type: EXPERIMENTAL
Intervention: Diltiazem (1.0 mg administered intracoronarily, distal from the stenosis)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30621471

Group type: EXPERIMENTAL
Intervention: Guluronic acid (G2013) 500 mg orally twice a day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guluronic acid (G2013)
Number of subjects: 0
Study: 28315478

Group type: EXPERIMENTAL
Intervention: Nursing home-based integrated palliative care teams
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 31
Study: 25068947

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 10 mg/kg intravenously 5 min before skin incision
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 124
Study: 23297844

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D3 supplementation (600 mg elemental calcium and 125 IU vitamin D3) with energy-restricted diet (‐500 kcal/d)
Number of subjects: 53
Study: 21296263

Group type: EXPERIMENTAL
Intervention: Acupoints mesotherapy (ACP mesotherapy, n=33)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Trigger point mesotherapy (TRP mesotherapy, n=29)
Number of subjects: 62
Study: 19131454

Group type: EXPERIMENTAL
Intervention: Subsidised nicotine replacement therapy (NRT) plus multisession counselling from the quitline
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Usual quitline service only (comparison group)
Number of subjects: 1377